In this analysis, Scott Mazza of Vitality CBD reviews recent peer-reviewed studies examining cannabidiol in the context of opioid dependence, including research on opioid reward, pain, and CBD’s interaction with naloxone. He emphasizes that these findings are early, and that widespread mislabeling, contamination, and the absence of regulatory oversight mean nothing in this literature translates into safe clinical use today. The article argues that FDA guidance, medical-grade production standards, and routine third-party testing are the preconditions for CBD to be studied credibly as part of the response to the opioid crisis.

In this guest column, Scott Mazza of Vitality CBD walks through emerging peer-reviewed research on cannabidiol and opioid dependence, including work on opioid reward, pain, and CBD’s interaction with naloxone. Mazza’s argument is regulatory rather than clinical: research at this stage says nothing useful about products that cannot demonstrate medical-grade purity, potency, and batch consistency, and most of what is on the market cannot. The article stresses that any future clinical application will depend on stricter regulation, independent testing, and clearing out the low-quality products that currently make the category impossible to evaluate.

In this policy-focused opinion piece, Scott Mazza of Vitality CBD examines how court-ordered injunctions and regulatory uncertainty have stalled New York’s adult-use cannabis retail rollout, leaving qualified applicants in limbo. Drawing on firsthand experience pursuing a retail license in an affected region, Mazza outlines the consequences of delayed guidance, uneven enforcement against gray-market operators, and mounting legal costs. The article argues that clearer timelines, transparency around standard licensing, and stronger action against illicit sales are essential to restoring fairness and stability in New York’s legal cannabis market.

In this firsthand product review, She Scribes explores consumer perceptions of hemp-derived CBD through personal testing of multiple offerings from Vitality CBD, including full-spectrum oils and topical salves. The article emphasizes common themes in the CBD market, such as variability in individual response, the importance of product quality, and third-party testing, while candidly documenting mixed results across pain relief, relaxation, and post-surgery recovery. Positioned as a lifestyle and wellness perspective rather than a clinical evaluation, the piece reflects how everyday consumers navigate CBD amid broad claims and uneven industry standards.

In this guest column, Scott Mazza of Vitality CBD explains how terpenes (the aromatic compounds in cannabis) contribute to distinct physiological effects and play a critical role alongside cannabinoids in the entourage effect. Citing a large-scale study analyzing thousands of real-world consumption sessions, Mazza highlights evidence that specific terpene profiles are associated with different outcomes for pain, anxiety, and depression. The article argues that moving beyond strain names toward chemistry-based classification could improve transparency, product selection, and medical credibility across both cannabis and CBD markets.

In this evidence-focused commentary, Scott Mazza of Vitality CBD examines what current research does (and does not) support regarding CBD’s role in women’s health. He reviews early findings on menopause-related symptoms, anxiety, and inflammation while cautioning that the largely unregulated CBD market has enabled misleading claims and inconsistent product quality. The article emphasizes responsible use, third-party testing, and the need for continued clinical research as the sector matures toward more credible, science-led outcomes.

In this wellness feature, Scott Mazza of Vitality CBD discusses emerging interest in CBD’s potential role in sexual wellbeing, particularly around anxiety, relaxation, and sensory awareness. The evidence he works from is survey data, anecdotal reports, and existing research on stress and anxiety rather than anything specific to intimacy, and what surfaces in it is people describing feeling present and at ease rather than any measured effect. The article also emphasizes individualized dosing considerations, especially for plus-size consumers, and the importance of choosing third-party tested CBD products for safety and consistency.

In this January 2023 CBD industry roundup, Leafly reports on shifting regulatory and market signals, including Google’s partial rollback of its CBD advertising ban, early indications of forthcoming FDA regulation, and international developments such as France legalizing hemp flower. The article also highlights independent testing that exposed widespread CBD mislabeling in gummies, reinforcing concerns about product quality and oversight. Within this broader context, Vitality CBD is featured for its full-spectrum tincture, positioned as a standards-driven product amid growing scrutiny of safety, labeling accuracy, and manufacturing practices.

This regulatory analysis examines growing congressional pressure on the FDA over its prolonged inaction on hemp-derived CBD, including an investigation led by the U.S. House Oversight Committee. Scott Mazza of Vitality CBD argues that regulatory paralysis has enabled bad actors and unsafe products to proliferate, calling for clear federal oversight on CBD, dietary supplements, and Delta-8. The article frames forthcoming FDA decisions as critical to restoring consumer safety, industry credibility, and regulatory accountability.

In this expert-led analysis, Scott Mazza of Vitality CBD explains why the “entourage effect”, the synergistic interaction of cannabinoids, terpenes, and flavonoids, is increasingly central to understanding CBD efficacy. Drawing on emerging clinical evidence, including anxiety studies comparing full-spectrum products to CBD isolates, Mazza outlines how full-spectrum formulations may achieve therapeutic effects at lower doses with fewer side effects. The article emphasizes the need for rigorous research to move the entourage effect from theory to practice and to inform higher scientific and manufacturing standards across the CBD industry.

In this guest column, Scott Mazza of Vitality CBD outlines how emerging clinical research, particularly phase 2 data on anxiety and studies on menopause, signals a shift from anecdotal claims toward scientific validation of CBD. Mazza argues that regulatory inaction around CBD, Delta-8, and dietary supplement status continues to hinder industry legitimacy, calling for clearer federal oversight and enforcement against low-quality products. He also points to changing social attitudes, especially in sports and mainstream sponsorships, as evidence that CBD is entering a more mature and credible phase heading into 2023.

In this year-in-review analysis, NutraIngredients examines how the U.S. CBD market in 2022 shifted away from hype toward scientific validation, regulatory scrutiny, and mainstream acceptance. Scott Mazza of Vitality CBD highlights growing clinical evidence, particularly in anxiety, women’s health, and recovery, as a key driver of consumer trust and industry maturity. The article positions science-led companies and clearer regulation as central to CBD’s long-term credibility and integration into wellness and sports markets.